ArticleAntimicrobial agents and chemotherapy2008
Immunomodulatory effects of voriconazole on monocytes challenged with Aspergillus fumigatus: differential role of Toll-like receptors.
Article in Antimicrobial agents and chemotherapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 53 citations in OpenAlex.
- Voriconazole treated human monocyte derived dendritic cells exhibit modulatory features with augmented surface expression of maturation and stimulatory markers.Molecular biology reports · 2026Article
- Hematological diseases-related mucormycosis: A retrospective single center study.PLoS neglected tropical diseases · 2025Article
- Interplay between fungal infections and autoimmunity: mechanisms and therapeutic perspectives.EMBO molecular medicine · 2025Review
- Antifungals influence the immune-related transcriptomic landscape of human monocytes after Aspergillus fumigatus infection.Scientific reports · 2022Article
- Magnesium impairs Candida albicans immune evasion by reduced hyphal damage, enhanced β-glucan exposure and altered vacuole homeostasis.PloS one · 2022Article
- Impact of immunosuppressive and antifungal drugs on PBMC- and whole blood-based flow cytometric CD154Medical microbiology and immunology · 2020Article
- Efficacy of Voriconazole against Aspergillus fumigatus Infection Depends on Host Immune Function.Antimicrobial agents and chemotherapy · 2020Article
- The Role of Pentraxin 3 in Aspergillosis: Reality and Prospects.Mycobiology · 2020Review
- Antifungal Drugs Influence Neutrophil Effector Functions.Antimicrobial agents and chemotherapy · 2019Article
- Voriconazole-refractory invasive aspergillosis.The Korean journal of internal medicine · 2017Review
- Interaction of THP-1 Monocytes with Conidia and Hyphae of DifferentFrontiers in immunology · 2017Article
- In vitro and in vivo study on the effect of antifungal agents on hematopoietic cells in mice.Experimental biology and medicine (Maywood, N.J.) · 2015Article
- Treatment options in Invasive Aspergillosis.Current treatment options in infectious diseases · 2014Article
- The impact of antifungals on toll-like receptors.Frontiers in microbiology · 2014Review
- Effect of PTX3 and voriconazole combination in a rat model of invasive pulmonary aspergillosis.Antimicrobial agents and chemotherapy · 2012Article
- Role of innate immune receptors in paradoxical caspofungin activity in vivo in preclinical aspergillosis.Antimicrobial agents and chemotherapy · 2012Article
- Systemic biomarkers of inflammation and haemostasis in patients with chronic necrotizing pulmonary aspergillosis.BMC infectious diseases · 2012Article
- Direct interaction studies between Aspergillus fumigatus and human immune cells; what have we learned about pathogenicity and host immunity?Frontiers in microbiology · 2012Article
- Eradication of the commensal intestinal microflora by oral antimicrobials interferes with the host response to lipopolysaccharide.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2010Article
- Innate immunity to Aspergillus species.Clinical microbiology reviews · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
Voriconazole (VRC) has activity against Aspergillus fumigatus, the most frequent cause of invasive aspergillosis in immunocompromised patients. The combination of VRC and A. fumigatus hyphae induced a more pronounced profile of expression of genes encoding inflammatory molecules in human monocytes than Aspergillus alone did. Herein, we provide further evidence of the potential mechanism underlying this immunomodulatory effect of VRC on human monocytes in response to A. fumigatus hyphae. A significant additive antifungal effect was shown when VRC was combined with monocytes against A. fumigatus hyphae. Both A. fumigatus hyphae and VRC induced pronounced profiles of mRNA and protein expression of Toll-like receptor 2 (TLR2) as well as tumor necrosis factor alpha (TNF-alpha) in THP-1 monocytic cells compared to untreated cells. The VRC-induced increase was greater than that induced by hyphae. The combination of VRC and hyphae increased mRNA and protein expression of TLR2 and TNF-alpha to even higher levels than did either VRC or hyphae alone. In contrast, TLR4 expression, both at the mRNA and protein levels, was not increased by either VRC or hyphae or their combination. In addition, significantly more NF-kappaB was translocated to the nuclei of THP-1 cells treated with VRC than untreated cells. While VRC induced more NF-kappaB than hyphae did, treatment with the combination of the two factors induced the greatest NF-kappaB expression. The pronounced profile of TLR2 signaling, TNF-alpha expression, and NF-kappaB activation in the presence of VRC suggests an immunomodulatory effect leading to a more efficient response to A. fumigatus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.